Participated · Series C · Jul 2022

Cleerly offers FDA-cleared, value-based diagnostic solutions driven by machine intelligence to enable comprehensive phenotyping of coronary artery disease from advanced non-invasive CT imaging. Its technology evaluates coronary CT angiograms to identify, characterize, and quantify atherosclerotic plaque build-up in artery walls, aiming to improve assessment of heart-attack risk versus historical surrogate markers. The company says its approach improves diagnostic certainty for physicians, helps personalize therapeutic choices, and can reduce total costs of care. Cleerly has more than a dozen ongoing multicenter clinical trials and is running an international registry expected to enroll more than 100,000 patients over the next decade. The company plans to expand its team, extend commercial reach to broaden patient and physician access across the continuum of disease presentation, and invest in large-scale outcomes research to establish its model as a standard of care. Financially, Cleerly recently completed a major funding round that materially increases resources for these initiatives. Cleerly provides a digital care pathway that uses non-invasive coronary CT angiography and AI-enabled, FDA-cleared software to phenotype coronary artery disease for heart attack prevention. The platform is built on more than a decade of research from the Dalio Institute for Cardiovascular Imaging at NewYork-Presbyterian and Weill Cornell Medicine, using millions of annotated lab images and over two dozen proprietary algorithms. Cleerly’s research included large-scale clinical trials involving more than 50,000 patients, which underpins its ability to quantify and characterize the presence, extent, severity and type of coronary artery disease. Its solutions include clinician-facing tools that translate advanced imaging into actionable data, patient-facing interactive tools to improve health literacy, and quantitative measures to track disease changes over time. With $43M in Series B financing and total funding of $54M, Cleerly plans to scale commercial reach, expand operational capabilities and strategic partnerships, and continue industry-leading research and development. The company was founded in 2017 and is headquartered in New York City.

Participated · Series B · Jun 2020

Shattuck Labs is a clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of dual-function fusion proteins for oncology and autoimmune disease. The ARC platform consolidates checkpoint blockade and tumor necrosis factor receptor superfamily (TNFRSF) agonism into single therapeutics. Its lead program, SL-279252 (PD1-Fc-OX40L), is being studied in a Phase I trial in collaboration with Takeda Pharmaceuticals, and SL-172154 (SIRPα-Fc-CD40L) is planned to begin Phase I enrollment. The company anticipates adding another clinical program in 2021 and continuing to expand its pipeline. Shattuck has offices in Durham, North Carolina and Austin, Texas. It recently closed a $118 million Series B equity financing to accelerate clinical development of multiple programs.

Participated · Seed · Mar 2018

Eden Health operates a nationally available concierge medical practice that combines telehealth, in-person primary care, behavioral health, and insurance navigation into a single care model. Patients reach a continuous Care Team via chat and video 24/7 and see the same clinicians in-person when needed, enabling ongoing relationships and historical knowledge of patient health. The company distributes services through employers and commercial real estate building landlords and has become a benefits partner for more than 100 employers across finance, retail, real estate, and technology over the past four years. Eden Health raised $60M in a Series C (bringing total funding to $100M) and plans to use proceeds to extend its Virtual Care platform, expand brick-and-mortar medical office presence to several new major U.S. metropolitan areas, and build integrations for third-party healthcare services. The business was launched in 2017 and is led by CEO Matt McCambridge. Eden Health operates a direct-to-employer healthcare delivery model that combines in-person and virtual care for mid-market companies. The company partners with employers to provide integrated benefits including primary care, triage, testing, and workplace health programs. Over four years it has become a benefits partner for more than 33,000 employees across more than 100 employers in industries such as finance, retail, real estate and technology. Since the start of the COVID-19 outbreak Eden Health has implemented evidence-based, medically informed plans, real-time monitoring, proactive outreach, and team-based care to support workforce health. It introduced a comprehensive back-to-work program including COVID-19 screening, virtual primary care, PCR testing, on-site antibody testing, immediate triage and patient consults. The company is led by co-founder and CEO Matt McCambridge and recently raised $25M in a Series B round, bringing total funding to $39M. Eden Health is a NYC-based employer-focused provider of integrated primary care, mental healthcare and insurance navigation. The company delivers services via an employee app that pairs workers with a personal care team for 24/7 digital care, same-day in-person visits at its medical office, specialist guidance and referrals, and insurance navigation. Led by co-founder and CEO Matt McCambridge, Eden launched in 2018 and has rolled out to multiple states. The company raised a Series A and intends to use the proceeds to expand its integrated solution nationwide by the end of the year. Eden Health is a New York City-based personal health platform focused on simplifying healthcare for employees and reducing employer expenses. Its platform offers 24/7 digital care (instant chat with providers), same-day in-person care at its clinics, specialist referrals and second opinions, and insurance navigation including prior authorizations and claims support. The company partners with mid-size and high-growth employers such as Yext, Insight Venture Partners, NewsCred and Tapad. The service is currently available in Greater New York City and New Jersey, with plans to expand into additional markets. Led by co-founder and CEO Matt McCambridge, Eden Health raised $4M in seed funding to continue expanding its reach.

Participated · Series E · Aug 2016

Torax Medical develops and markets products designed to treat sphincter disorders using its Magnetic Sphincter Augmentation (MSA) technology platform. It currently markets the LINX Reflux Management System for gastroesophageal reflux disease (GERD) and the FENIX Continence Restoration System for fecal incontinence in the U.S. and Europe. Led by President and CEO Todd Berg and newly appointed Chief Commercial Officer Chas McKhann, the company focuses on chronic diseases related to weak sphincter muscles. Torax completed a $25M Series E financing to support commercial scaling of its product platform. The company is based in St. Paul, Minn. Torax Medical develops and markets Magnetic Sphincter Augmentation (MSA) implants composed of interlinked titanium beads with magnetic cores to augment defective sphincter muscles. Its lead product, the LINX Reflux Management System for GERD, was approved by the US FDA in March following a unanimous FDA advisory panel recommendation. LINX is marketed in the USA and Europe; the company’s FENIX Continence Restoration System for fecal incontinence is marketed in Europe. Devices are implanted via standard minimally invasive laparoscopic or surgical procedures. The company is headquartered in St. Paul, Minnesota and is privately held. Proceeds from the recent financing will be used to expand commercialization efforts for its family of sphincter augmentation products. Torax Medical won CE Mark approval in the European Union for its Linx implantable device to treat gastro‑esophageal reflux disease. The Linx is a ring of interlinked miniature titanium beads with magnetic cores placed around the esophagus to help the sphincter prevent reflux; the beads separate momentarily to allow swallowing. The device has been implanted in more than 150 patients in the U.S. and Europe in clinical trials. It has not yet been cleared for sale in the U.S.; Torax completed patient enrollment in a pivotal clinical trial in September and could seek FDA approval by the end of the year if the trial goes well. The company has raised $31.5M in equity to date, including an $18M Series C (with $3M from Kaiser Permanente Ventures) and earlier Series B and A financings. Torax was founded in 2002, has about 20 employees, and is led by co‑founder and CEO Todd Berg, formerly of St. Jude Medical.

Participated · Equity · Sep 2015

PerfectServe provides a comprehensive, secure communication and collaboration platform for healthcare, anchored by its flagship solution, PerfectServe Synchrony. Synchrony unites physicians, nurses and other care team members across the continuum and automatically identifies and provides immediate access to the right care team member to facilitate timely interaction. More than 100,000 clinicians at organizations such as Advocate Healthcare, Ascension Health, Covenant Medical Group, Hoag, MemorialCare Health System, Orlando Health, St. Joseph Health, and WellStar rely on PerfectServe. The company says it will use the $21 million financing to advance research and development of Synchrony and bring the product’s full set of capabilities to market. Management positions the funding to expand platform capabilities to meet growing demand for secure, communication-driven workflows and to improve care coordination, patient experience, and outcomes. Headquartered in Knoxville, Tennessee, PerfectServe has been serving healthcare provider organizations since 2000. PerfectServe offers a clinical communication platform designed to connect clinicians and push relevant clinical information to the right physician. Led by president and CEO Terry Edwards, the company processes more than 30 million transactions annually. It connects more than 20,000 physicians in health systems and medical practices across 154 U.S. markets. PerfectServe intends to use new funding to expand its national network of services and invest in innovations. The platform is positioned to improve clinician coordination and information delivery across a broad set of care settings.